Beyond The Abstract - Pathological Evidence Of Necrosis In Recurrent Renal Mass Following Treatment With Sunitinib

UroToday.com - Sunitinib is a highly potent, selective inhibitor of certain protein tyrosine kinases, including VEGF-R types 1 to 3, PDGF-R- , and PDGF-R-ß. Preclinical data suggest that sunitinib has antitumor activity that may result from both inhibition of angiogenesis and direct antiproliferative effects on certain tumor cell types.

More: continued here

Filed under: Urology on January 29th, 2008